LinkedIn Icon
October 22-24, 2018
London, UK

 

 

Speakers

Expand/Collapse

Karen Aiach
Founder & CEO
Lysogene

Founder and CEO of Lysogene, Ms. Aiach is also the mother of a child with MPS IIIA. She has a strong business background starting her career with Arthur Andersen specializing in audit and transaction services. Her entrepreneurial experience includes founding and running a financial business consultancy. From 2008 to 2009, Ms. Aiach served as a Member of the Pediatric Committee at the European Medicines Agency (EMA), established in accordance with the European Pediatric Regulation, as a patient representative. In 2008, she also served on the French Ethical Review Board CCPPRB at Ambroise Paré Hospital.  Ms. Aiach has been involved with several not-for-profit organizations engaged in advocacy and research in the field of rare diseases such as Alliance Sanfilippo and Eurordis, where she served on the board as treasurer from 2010 to 2011. She is a founding executive member of the International Rare Diseases Research Consortium (IRDiRC). Ms. Aiach graduated from the ESSEC Business School and majored in Economics.

Conference Day Two

Wednesday, 24th October, 2018

13.45 | Presentation Details To Be Confirmed

Celine Bouquet
Preclinical Manager,
GenSight Biologics

Conference Day One

Tuesday 23rd October, 2018

12.00 | Supporting Clinical Development in the Gene Therapy Space Through Biodistribution & Immunogenicity Assessment

Emily Culme-Seymour
Clinical Development Scientist, Rare Diseases
GSK

Conference Day One

Tuesday 23rd October, 2018

16.30 | Panel Discussion: Strategic Partnerships to Achieve Commercialisation: What are the Trends & What Does the Future Look Like?

Omar Dabbous
VP, Global Health Economics & Outcomes Research
AveXis

Conference Day One

Tuesday 23rd October, 2018

09.30 | Panel Discussion: Evaluating Value-Based Pricing Models for Gene Therapy Products

Anne Douar
CDO
Vivet Therapeutics

Conference Day Two

Wednesday, 24th October, 2018

11.00 | Finding the Right Dose From Mice to Human: A Complex Equation

Alan Griffith
MSAT Manager
MeiraGTx

Conference Day Two

Wednesday, 24th October, 2018

11.30 | Panel Discussion: The Next Step – Pioneering Gene Therapies in More Common Diseases

08.30 | Scaling Manufacturing to Deal with the Demands of Commercial Gene Therapy Products

Matthew Hankinson
Associate Director, Analytical Development
Allergan

Conference Day Two

Wednesday, 24th October, 2018

09.30 | Developing Effective Process Characterisation & Analytical Tools

Sven Kili
VP, Head of Cell & Gene Therapy Development
GSK

Conference Day One

Tuesday 23rd October, 2018

17.00 | Chair’s Closing Remarks

11.15 | Establishing Effective Manufacturing & Regulatory Standards

08.20 | Chair’s Opening Remarks

Nerissa Kreher
CMO
Avrobio

Conference Day One

Tuesday 23rd October, 2018

11.30 | Incorporating Patient Input & Patient Reported Outcome Measures: A Fabry Clinical Trial Example

Aurelie Lambert
Manager, Regulatory Affairs EU
BioMarin

Conference Day Two

Wednesday, 24th October, 2018

15.15 | Tackling the Additional Complexities of GMO Applications to Save Crucial Development Time

Christine Le Bec
Head of CMC Analytics
Genethon

Pre Conference Workshop

Monday 22 October 2018

13.00 | Overcoming Analytical Challenges Encountered Throughout the Development of Gene Therapies

Robert Morgan
Executive Director, Regulatory Affairs
Nightstar Therapeutics

Conference Day Two

Wednesday, 24th October, 2018

14.15 | Engaging European Regulators Around Key Issues Throughout the Gene Therapy Development Process

Jan Nilsson
CEO
CombiGene

Conference Day Two

Wednesday, 24th October, 2018

11.30 | Panel Discussion: The Next Step – Pioneering Gene Therapies in More Common Diseases

Detlev Parow
Head, Pharmaceuticals Department
DAK-Gesundheit

Conference Day One

Tuesday 23rd October, 2018

09.30 | Panel Discussion: Evaluating Value-Based Pricing Models for Gene Therapy Products

09.00 | The Payer Perspective: Investigating how Gene Therapies Require a Fundamental Change in Healthcare Delivery

Steven Pearson
Founder & President
ICER

Conference Day One

Tuesday 23rd October, 2018

09.30 | Panel Discussion: Evaluating Value-Based Pricing Models for Gene Therapy Products

08.30 | How Will Value Frameworks and Budget Impact Analysis be Used to Evaluate Gene Therapies?

Isabelle Pengué Koyi
VP, Regulatory Affairs & Quality
GenSight Biologics

Conference Day Two

Wednesday, 24th October, 2018

15.45 | Managing Late-Stage Gene Therapy Development in Preparation for MA/BLA Applications

Markus Peters
CCO
Agilis Biotherapeutics

Conference Day One

Tuesday 23rd October, 2018

16.00 | Panel Discussion: Understanding Unique Challenges Involved in Developing Gene Therapies in a Biotech Environment

Hanspeter Rottensteiner
Director, Drug Discovery Gene Therapy
Shire

Conference Day Two

Wednesday, 24th October, 2018

09.00 | Navigating the Capacity Bottleneck – Contrasting In-House and External Manufacturing Options & Understanding the Shire Approach

Dominic Schmidt
Partner
Syncona

Conference Day One

Tuesday 23rd October, 2018

14.00 | Panel Discussion: Gaining Insights into How Investors View the Gene Therapy Space

Jeff Sevigny
CMO
Prevail Therapeutics

Conference Day Two

Wednesday, 24th October, 2018

11.30 | Panel Discussion: The Next Step – Pioneering Gene Therapies in More Common Diseases

Sander van Deventer
CSO, uniQure & Operating Partner
Forbion Capital Partners

Conference Day One

Tuesday 23rd October, 2018

14.00 | Panel Discussion: Gaining Insights into How Investors View the Gene Therapy Space

Samantha Vieira
Senior Director, Programme Management
Nightstar Therapeutics

Conference Day One

Tuesday 23rd October, 2018

16.00 | Panel Discussion: Understanding Unique Challenges Involved in Developing Gene Therapies in a Biotech Environment

Conference Day Two

Wednesday, 24th October, 2018

13.15 | Developing & Commercializing Novel One-Time Treatments for Patients Suffering from Rare Inherited Retinal Diseases that would Otherwise Progress To Blindness – the Nightstar Approach

Hai Zhang
Director, Pharma M&A
Novartis

Conference Day One

Tuesday 23rd October, 2018

16.30 | Panel Discussion: Strategic Partnerships to Achieve Commercialisation: What are the Trends & What Does the Future Look Like?